Skip to main navigation
Bellicum Home
  • Platforms
    • Platforms
    • GoCAR™ Technology
    • CaspaCIDe® Safety Switch
  • Pipeline
    • Pipeline
    • GoCAR-T®
  • Publications
    • Scientific Publications
  • About Us
    • Management Team
    • Board of Directors
    • Advisory Board
    • Careers
  • Investors & Media
    • Investor Center
    • News & Events
      • Press Releases
      • Events and Presentations
      • Email Alerts
    • Stock Information
      • Stock Quote
      • Stock Chart
      • Historical Price Lookup
      • Analyst Coverage
    • Financial Information
      • Annual Reports & Proxies
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Committee Composition
    • Investor FAQ
    • Contact Us
  • Search Close
Bellicum Home
Mobile Menu Mobile Close

Platforms

  • Platforms
  • GoCAR™ Technology
  • CaspaCIDe® Safety Switch

Pipeline

  • Pipeline
  • GoCAR-T®

Publications

  • Scientific Publications

About Us

  • Management Team
  • Board of Directors
  • Advisory Board
  • Careers

Investors & Media

  • Investor Center
  • News & Events
    • Press Releases
    • Events and Presentations
    • Email Alerts
  • Stock Information
    • Stock Quote
    • Stock Chart
    • Historical Price Lookup
    • Analyst Coverage
  • Financial Information
    • Annual Reports & Proxies
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Committee Composition
  • Investor FAQ
  • Contact Us

Search

Inpage Nav - News & Events

  • Press Releases
  • Events and Presentations
  • Email Alerts

Press Releases

 

Press Releases

  • Date

    Title

  • 03/14/23

    Bellicum Discontinues Phase 1/2 Trials and Initiates Evaluation of Strategic Alternatives

  • 02/16/23

    Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium

  • 01/31/23

    CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • 01/31/23

    Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

  • 01/19/23

    Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium

Next: Events and Presentations

Platforms

  • Platforms
  • GoCAR™ Technology
  • CaspaCIDe® Safety Switch

Pipeline

  • Pipeline
  • GoCAR-T®

Publications

  • Scientific Publications

About Us

  • Leadership Team
  • Board of Directors
  • Advisory Board
  • Careers

Investors & Media

  • Investor Center
  • News & Events
  • Stock Information
  • Financial Information
  • Corporate Governance
  • Investor FAQ
  • Contact Us

Copyright ©2023 Bellicum Phamaceuticals, Inc. All rights reserved.

  • Contact Us
  • Privacy Policy
  • Terms of Use
  • twitter
  • linkedin